The developed formulation was able to specifically reach the tumor cells with a high level of expression of HER2 during in vivo studies using an orthotopic human ovarian cancer xenograft model, reducing significantly the growth of primary tumor and metastasis. This evidence concerns the gene ERBB2 and neoplasm.